New Adjuvant Therapies for Obesity-Related Disorders Associated with Meta-Neuroinflammation
Pharmaceuticals · 17.05.2026 · 19 (5) · 786
DOI: 10.3390/ph19050786 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 17.05.2026. Verfasst von Flaminia Coluzzi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome, 00189 Rome, Italy. Die Arbeit nennt 283 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Epitech Group S.p.A.
Abstract (Originalsprache)
Obesity is a complex, heterogeneous, chronic, and progressive disease, which correlates with an augmented risk of developing several comorbidities, including painful conditions, such as osteoarthritis. In this review, authors present for the first time the term meta-neuroinflammation for describing how the chronic, low-grade systemic inflammation, that occurs in obesity, may trigger oxidative stress and neuroinflammatory processes. Both the peripheral and the central nervous system are involved in neuroinflammation, leading to central sensitization and pain chronification, which leads to the observed increased incidence in obese patients of chronic pain syndromes, particularly osteoarthritis, low back pain, fibromyalgia, headache, and diabetic peripheral neuropathy. Possible mechanisms by which obesity may cause meta-neuroinflammation include adiposopathy, gut microbiota dysbiosis, and compromised integrity of blood–brain barrier, which could explain obesity-related depressive and neurodegenerative disorders. Preclinical data suggest the meta-neuroinflammation as a potential target of treatment in obese patients with degenerative joint disease. Based on these observations, targeted therapeutic strategies may include systemic administration of ultramicronized palmitoylethanolamide (um-PEA), well known for its neuroprotective, anti-neuroinflammatory, and analgesic actions, and comicronized PEA–rutin and hydroxytyrosol to restore intestinal eubiosis, with beneficial effects on body weight and mental disorders. Finally, Adelmidrol, as a PEA congener, could be considered for mitigating intra-articular meta-neuroinflammation in knee osteoarthritis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome, 00189 Rome, Italy.
- Unit Anesthesia, Intensive Care and Pain Therapy, Sant'Andrea University Hospital, 00189 Rome, Italy.
- Department of Experimental Medicine, PhD School in Biochemistry and Molecular Biology, University of Rome Tor Vergata, 00133 Rome, Italy.
- Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
- UOSD Nephrology and Dialysis, Policlinico Tor Vergata, 00133 Rome, Italy.
- Department of Clinical Sciences, Catholic University Our Lady of Good Counsel, 1000 Tirana, Albania.
ORCID-Profile: Flaminia Coluzzi, Kevin Cornali, Annalisa Noce
Förderung
- Epitech Group S.p.A
Zitieren
APA
Coluzzi, F., Cornali, K., Scerpa, M. S., & Noce, A. (2026). New Adjuvant Therapies for Obesity-Related Disorders Associated with Meta-Neuroinflammation. Pharmaceuticals, 19(5), 786. https://doi.org/10.3390/ph19050786
Vancouver
Coluzzi F, Cornali K, Scerpa MS, Noce A. New Adjuvant Therapies for Obesity-Related Disorders Associated with Meta-Neuroinflammation. Pharmaceuticals. 2026;19(5):786. doi:10.3390/ph19050786
BibTeX
@article{Coluzzi2026,
author = {Coluzzi, Flaminia and Cornali, Kevin and Scerpa, Maria Sole and Noce, Annalisa},
title = {New Adjuvant Therapies for Obesity-Related Disorders Associated with Meta-Neuroinflammation},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {5},
pages = {786},
doi = {10.3390/ph19050786}
}
EUVIMED